357 related articles for article (PubMed ID: 14622169)
41. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
42. Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography.
Flores G; Liang JJ; Sierra A; Martínez-Fong D; Quirion R; Aceves J; Srivastava LK
Neuroscience; 1999; 91(2):549-56. PubMed ID: 10366012
[TBL] [Abstract][Full Text] [Related]
43. On the distribution patterns of D1, D2, tyrosine hydroxylase and dopamine transporter immunoreactivities in the ventral striatum of the rat.
Jansson A; Goldstein M; Tinner B; Zoli M; Meador-Woodruff JH; Lew JY; Levey AI; Watson S; Agnati LF; Fuxe K
Neuroscience; 1999 Mar; 89(2):473-89. PubMed ID: 10077329
[TBL] [Abstract][Full Text] [Related]
44. Rats bred for enhanced apomorphine susceptibility have elevated tyrosine hydroxylase mRNA and dopamine D2-receptor binding sites in nigrostriatal and tuberoinfundibular dopamine systems.
Rots NY; Cools AR; Bérod A; Voorn P; Rostène W; de Kloet ER
Brain Res; 1996 Feb; 710(1-2):189-96. PubMed ID: 8963658
[TBL] [Abstract][Full Text] [Related]
45. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
Bouchez G; Sensebé L; Vourc'h P; Garreau L; Bodard S; Rico A; Guilloteau D; Charbord P; Besnard JC; Chalon S
Neurochem Int; 2008 Jun; 52(7):1332-42. PubMed ID: 18372079
[TBL] [Abstract][Full Text] [Related]
46. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study.
Javoy-Agid F; Hirsch EC; Dumas S; Duyckaerts C; Mallet J; Agid Y
Neuroscience; 1990; 38(1):245-53. PubMed ID: 1979431
[TBL] [Abstract][Full Text] [Related]
47. Mechanism of action of dopaminergic agents in Parkinson's disease.
Koller WC; Rueda MG
Neurology; 1998 Jun; 50(6 Suppl 6):S11-4; discussion S44-8. PubMed ID: 9633680
[TBL] [Abstract][Full Text] [Related]
48. Dopamine-deficient mice are hypersensitive to dopamine receptor agonists.
Kim DS; Szczypka MS; Palmiter RD
J Neurosci; 2000 Jun; 20(12):4405-13. PubMed ID: 10844009
[TBL] [Abstract][Full Text] [Related]
49. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.
Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F
Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880
[TBL] [Abstract][Full Text] [Related]
50. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
Ryoo HL; Pierrotti D; Joyce JN
Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147
[TBL] [Abstract][Full Text] [Related]
51. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
[TBL] [Abstract][Full Text] [Related]
52. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease.
Kastner A; Hirsch EC; Agid Y; Javoy-Agid F
Brain Res; 1993 Mar; 606(2):341-5. PubMed ID: 8098254
[TBL] [Abstract][Full Text] [Related]
53. Dopamine receptors and transporters in Parkinson's disease and schizophrenia.
Seeman P; Niznik HB
FASEB J; 1990 Jul; 4(10):2737-44. PubMed ID: 2197154
[TBL] [Abstract][Full Text] [Related]
54. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.
Bezard E; Gray D; Kozak R; Leoni M; Combs C; Duvvuri S
CNS Neurol Disord Drug Targets; 2024; 23(4):476-487. PubMed ID: 36999711
[TBL] [Abstract][Full Text] [Related]
55. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
[TBL] [Abstract][Full Text] [Related]
56. Modification of dopaminergic markers expression in the striatum by neonatal exposure to glutamate during development.
López-Pérez SJ; Vergara P; Ventura-Valenzuela JP; Ureña-Guerrero ME; Segovia J; Beas-Zárate C
Int J Dev Neurosci; 2005 Jun; 23(4):335-42. PubMed ID: 15927757
[TBL] [Abstract][Full Text] [Related]
57. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
58. Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography.
Tupala E; Hall H; Mantere T; Räsänen P; Särkioja T; Tiihonen J
Neuroimage; 2003 May; 19(1):145-55. PubMed ID: 12781734
[TBL] [Abstract][Full Text] [Related]
59. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study.
Kingsbury AE; Marsden CD; Foster OJ
Mov Disord; 1999 Mar; 14(2):206-18. PubMed ID: 10091611
[TBL] [Abstract][Full Text] [Related]
60. Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys.
Stephenson DT; Childs MA; Li Q; Carvajal-Gonzalez S; Opsahl A; Tengowski M; Meglasson MD; Merchant K; Emborg ME
Cell Transplant; 2007; 16(3):229-44. PubMed ID: 17503735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
